Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry Psychology and Neuroscience, King's College London, 16 De Crespigny Park, London, SE5 8AF, UK.
Division of Psychiatry, University College London, London, UK.
BMC Psychiatry. 2020 Apr 15;20(1):161. doi: 10.1186/s12888-020-02577-1.
Although Positive Behaviour Support (PBS) is a widely used intervention for ameliorating challenging behaviour (CB), evidence for its use in adults with intellectual disability (ID) and comorbid autism (ASD) is lacking. We report a planned subsidiary analysis of adults with both ASD and ID who participated in a randomised trial of PBS delivered by health professionals.
The study was a multicentre, cluster randomised trial conducted in 23 community ID services in England, participants were randomly allocated to either the delivery of PBS (n = 11 clusters) or to treatment as usual (TAU; n = 12). One-hundred and thirteen participants (46% of all participants in the trial) had a diagnosis of ID, autism spectrum disorder and CB (ASD+); (47 allocated to the intervention arm, and 66 to the control). CB (primary outcome) was measured with the Aberrant Behaviour Checklist total score (ABC-CT). Secondary outcomes included mental health status, psychotropic medication use, health and social care costs and quality adjusted life years (QALYs) over 12 months.
There were no statistically significant differences in ABC-CT between ASD+ groups randomised to the two arms over 12 months (adjusted mean difference = - 2.10, 95% CI: - 11.3 7.13, p = 0.655) or other measures. The mean incremental cost of the intervention per participant was £628 (95% CI -£1004 to £2013). There was a difference of 0.039 (95% CI - 0.028 to 0.103) for QALYs and a cost per QALY gained of £16,080.
Results suggest lack of clinical effectiveness for PBS delivered by specialist ID clinical teams. Further evidence is needed from larger trials, and development of improved interventions.
ClinicalTrials.gov: NCT01680276.
尽管正向行为支持(Positive Behaviour Support,PBS)是一种广泛用于改善挑战性行为(CB)的干预措施,但缺乏其在患有智力残疾(ID)和共患自闭症(ASD)的成年人中的应用证据。我们报告了一项针对参加专业健康人员提供的 PBS 随机试验的 ASD 和 ID 双重诊断成年人的计划附属分析。
该研究是在英格兰 23 个社区 ID 服务中心进行的一项多中心、集群随机试验,参与者被随机分配到 PBS 组(n=11 个集群)或常规治疗组(TAU;n=12)。共有 113 名参与者(试验中所有参与者的 46%)被诊断为 ID、自闭症谱系障碍和 CB(ASD+);(47 人被分配到干预组,66 人被分配到对照组)。CB(主要结局)用异常行为检查表总分(ABC-CT)进行测量。次要结局包括心理健康状况、精神药物使用、医疗保健费用和 12 个月的质量调整生命年(QALY)。
在 12 个月内,随机分配到两组的 ASD+ 组之间,ABC-CT 无统计学显著差异(调整后平均差异= -2.10,95%置信区间:-11.3 7.13,p=0.655)或其他措施。每个参与者干预的平均增量成本为 628 英镑(95%置信区间:-1004 至 2013 英镑)。QALY 差异为 0.039(95%置信区间:-0.028 至 0.103),每获得一个 QALY 的成本为 16080 英镑。
结果表明,由专业 ID 临床团队提供的 PBS 缺乏临床效果。需要更大规模的试验提供进一步证据,并开发出更好的干预措施。
ClinicalTrials.gov:NCT01680276。